Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation - 24/04/13
National Psoriasis Foundation
Reprint requests: Andrew Blauvelt, MD, 3710 SW US Veterans Hospital Rd., Mail Code R&D 55, Portland, OR 97239.Abstract |
An association between obesity and psoriasis has been reported. For a variety of reasons, obese persons with psoriasis are often more difficult to treat. We sought to review the literature on obesity and psoriasis and to discuss efficacy and safety data that could be utilized by clinicians who are making treatment decisions for obese persons with psoriasis. We performed a literature review using the terms “obesity and psoriasis” and “metabolic syndrome and psoriasis.” Evidence from relevant literature was evaluated and categorized according to the criteria of Shekelle et al (published 1999). Numerous reports cite an association between obesity and psoriasis. When compared with non-obese patients with psoriasis, obese patients with psoriasis are more likely to experience certain adverse effects to medications and are less likely to respond favorably to systemic therapies. The amount of category I evidence for objectively determining the best treatment choices for obese patients with psoriasis was scarce and thus did not allow for the development of a treatment algorithm that could be generally applied for all psoriasis patients who are obese. Efficacy and safety concerns affected by obesity are important considerations for clinicians who are making decisions on proper treatment of psoriasis.
Le texte complet de cet article est disponible en PDF.Abbreviations used : BMI, HDL, IFN-γ, IL, OR, PASI, TNF-⍺
Plan
| Funded by the National Psoriasis Foundation, Portland, OR. |
|
| Disclosures: Dr Bremmer has no disclosures to report. Dr Van Voorhees has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, Genentech, Incyte, Connetics, Warner Chilcott, Photomedix, Roche, and Synta; she also has a significant conflict of interest with Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech; she has been a clinical investigator for Amgen and Centocor. Dr Korman has been an investigator or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott; he has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has been a consultant or speaker for Abbott, Amgen, Astellas, Biogen Idec, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Blauvelt has been a consultant, investigator, or speaker for Abbott, Amgen, Centocor, Genentech, Anacor, Coria, Vascular Biogenics, PM Toleikis & Associates, MacroGenics, Eli Lilly, CombinatoRx, Cerimon, Barrier Therapeutics, Pfizer, and Novo Nordisk. |
Vol 63 - N° 6
P. 1058-1069 - décembre 2010 Retour au numéro
Article précédent
- Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: Evaluation of 126 cases
- Rola Al Dhaybi, Julie Powell, Catherine McCuaig, Victor Kokta
- Announcing a New Online Feature
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?